ACTRN12624001160527尚未招募1 期
The efficacy of psilocybin assisted psychotherapy (PAP) for treatment resistant obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), and anorexia nervosa (AN); a pilot, single-arm basket trial
Swinburne University0 个研究点目标入组 30 人开始时间: 2024年9月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 主要终点
- Obsessive-compulsive symptom severity (OCD participants)[Yale Brown Obsessive Compulsive Scale (YBOCS)- total score Baseline and 8-week post-baseline. ];Body-dysmorphic symptom severity (BDD participants)[Body Dysmorphic Disorder- Yale Brown Obsessive Compulsive Scale (BDD-YBOCS)- total score Baseline and 8-week post-baseline. ];Anorexia nervosa symptom severity (AN participants)[Eating disorder Examination Questionnaire (EDE)- severity score Baseline and 8-week post-baseline. ]
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •i)Adults aged 18 to 65 years.ii)Primary diagnosis of OCD, BDD or AN according to the DSM-5, determined by Structured Clinical Interview for DSM-5 Disorder (SCID-5), The Body Dysmorphic Disorder Diagnostic Module (BDD-DM) and Eating Disorder Examination (EDE).iii)Moderate to severe symptom severity indicated as a score 18 or greater on the YBOCS, 20 or greater on the BDD-YBOCS, 3 or greater on the shape and/or weight subscales of the EDE.iv)Treatment resistance; defined as 1-year of illness with continuing symptoms for at least 6-months despite adequate engagement in conventional interventions for the condition. Specifically, conventional therapies for each condition are defined as: OCD: a course of selective serotonin reuptake inhibitors (SSRIs) and at least one course of cognitive behavioural therapy (CBT) which must include exposure and response prevention (ERP) (Pallanti and Quercioli, 2006).BDD: two courses of psychotherapy and/or pharmacology treatment, including at least one course of cognitive behavioural therapy (CBT), adequatea course of SSRIs or serotonin-norepinephrine reuptake inhibitor (SNRI).AN: a course of SSRIs or SNRIs, and at least one in-patient admission or day patient program.v)Illness duration of at least 1- year vi)Absence of delusionality as indicated by a total score <18, and a score of <4 on the delusionality sub-scale on the BABS vii)Absence of mania symptoms (only minor) as indicated by a score <20 on the YMRSviii)If currently taking serotonergic antidepressants or atypical antipsychotics that block 5HT2A receptors, which can interfere with the mechanism of action of psilocybin, agree to, and can be, appropriately tapered off such concomitant medication with clinical team support.ix)Under the care of a psychiatrist, psychologist, physician, or GP.x)Proficient in English, such that their literacy and comprehension is sufficient for understanding the consent form and study questionnaires, as evaluated by study staff obtaining consent. xi)Participants who agree to be abstinent from illicit or extra-medical drug and alcohol use for at least 2 days prior to each psilocybin dosing.xii)Participants who agree to have their drug dosing sessions recorded to video for treatment fidelity and clinical supervision within the study team.xiii)Utilising effective contraception if female and of childbearing agexiv)Capacity to provide adequate inform consent; demonstrated by an estimated IQ >79 assessed by the Weschler Abbreviated Scale of Intelligence (WASI) to ensure that study instructions can be understood, and by a revised version of the Evaluation to sign an informed consent document for research to ensure appropriate understanding of trial requirements (DeRenzo et al., 1998).
排除标准
- •Psychiatric exclusions i)Lifetime history of serious suicide attempts requiring hospitalisation or current suicidal ideation with intent warranting immediate hospitalisation. ii)Current or past history of psychosis; DSM-5 criteria for Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), Bipolar I or II Disorder or Mania, determined by medical history and MINI assessment.iii)First degree relative with diagnosed Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), Bipolar I or II Disorder or Mania.iv)Presence of significant neurodevelopmental disorder (e.g., ADHD, autism, unremitting Tourette’s syndrome) that would reasonably impact the therapeutic effect of psilocybin. v)Currently meets DSM-5 criteria for Dissociative Disorder, Bulimia Nervosa, or significant personality disorder judged to be incompatible with establishment of rapport or safe exposure to psilocybin, determined by clinical interview.vi)Any current personal or situational factors that, in the opinion of the research team, might interfere with participation (for example, lacking social support, lacking a stable living situation, current domestic violence, or other ongoing trauma). vii)A history of childhood trauma or other factors leading to a complex case of OCD, BDD, or AN. General medical exclusions i)Any disorder with known CNS involvement or disease, including seizuresii)Hepatic dysfunction as indicated by the following values: iii)-- GGT > 3 x ULN (upper limit of norm)iv)-- AST > 3 x ULNv)-- ALT > 3 x ULNvi)-- Tot Bili > 3.0 mg/dL vii)Known conditions putting participant at risk for hypercalcaemia, Cushing's syndrome, hypoglycaemia, syndrome of inappropriate antidiuretic hormone secretion, or carcinoid syndrome. viii)Cardiovascular conditions: uncontrolled hypertension (Systolic >140 and diastolic >90), angina, a clinically significant ECG abnormality (e.g., atrial fibrillation), TIA in the last 6 months, stroke, or cerebrovascular disease, peripheral or pulmonary vascular disease (no active claudication). This could include patients presenting with abnormal QT interval prolongation at screening or with a history of this (QTc at screening above 440 ms for men and above 470 ms for women).ix)Renal insufficiency (creatinine clearance < 40 mL/min using the Cockcroft and Gault equation).x)Insulin-dependent diabetes; if taking oral hypoglycaemic agents only excluded if they also have a history of hypoglycaemia.xi)Females who are pregnant or nursing or are trying to get pregnant, or become pregnant during the study.xii)Current hypothyroidism not responsive to treatment or untreated hypothyroidism.xiii)Patients who weigh less than 40 kg or have a BMI <16 kg/m2.xiv)Medical instability as indicated by significant weight loss (>3 kg) during screening period, orthostatic heart rate or blood pressure.xv)Long-acting opioid pain medications (e.g., oxycodone sustained release, morphine sustained release -- which are usually taken at 12-hour intervals) will be allowed if the last dose occurred at least 6 hours before psilocybin administration; such medication will not be taken again until at least 6 hours after psilocybin administration. xvi)Macro-dose (i.e., dose large enough to have perceivable hallucinogenic/psychedelic effects) of any hallucinogen or psychedelic (including psilocybin, MDMA, LSD, mescaline, DMT, and other similar ha
结局指标
主要结局
Obsessive-compulsive symptom severity (OCD participants)[Yale Brown Obsessive Compulsive Scale (YBOCS)- total score Baseline and 8-week post-baseline. ];Body-dysmorphic symptom severity (BDD participants)[Body Dysmorphic Disorder- Yale Brown Obsessive Compulsive Scale (BDD-YBOCS)- total score Baseline and 8-week post-baseline. ];Anorexia nervosa symptom severity (AN participants)[Eating disorder Examination Questionnaire (EDE)- severity score Baseline and 8-week post-baseline. ]
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
Psilocybin for hospitalized patients with treatment-resistant depressiotreatment-resistant depressionCTIS2022-501857-35-00niversitair Ziekenhuis Gent100
已完成
2 期
Psilocybin-assisted psychotherapy for the treatment of depression and anxiety associated with life-threatening illnessDepression in terminal illness (any palliative condition including malignant and non-malignant terminal illnesses)Anxiety in terminal illness (any palliative condition including malignant and non-malignan terminal illnesses)Mental Health - AnxietyMental Health - DepressionCancer - Any cancerACTRN12619001225101St. Vincent's Hospital Melbourne35
尚未招募
2 期
Evaluating the management of treatment resistant depression with psychedelic (psilocybin) assisted psychotherapy (EMPACT)Treatment Resistant DepressionMental Health - DepressionACTRN12623001004651The Australian National University140
已完成
2 期
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression (EPIsoDE)F32.1F32.2F33.1F33.2Moderate depressive episodeSevere depressive episode without psychotic symptomsRecurrent depressive disorder, current episode moderateRecurrent depressive disorder, current episode severe without psychotic symptomsDRKS00024484Zentralinstitut für Seelische Gesundheit144
进行中（未招募）
2 期
Psilocybin-assisted psychotherapy for Generalised Anxiety DisorderACTRN12621001358831Monash University72